Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: Results of a randomized, controlled trial

Vaccine

Volumn 30, Issue 32, 2012, Pages 4728-4732

  Scheifele, David W ^a   Ward, Brian J ^b   Dionne, Marc ^c   Vanderkooi, Otto G ^d   Loeb, Mark ^e   Coleman, Brenda L ^f   Li, Yan ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Influenza vaccine, A H1N1pdm09 pandemic; Influenza vaccine, seasonal; Vaccine adjuvants

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADULT; AGE DISTRIBUTION; ARTHRALGIA; ARTICLE; ASTHMA; CANADA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTERVIEW; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SEROLOGY; SKIN REDNESS; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84862580022     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.029     Document Type: Article

References (15)

1. Girard M.P., Tam J.S., Assossou O.M., Kieny M.P. The 2009 A (H1N1) influenza pandemic: a review. Vaccine 2010, 28:4895-4902.
2. Ferguson M., Risi G., Davis M., Sheldon E., Baron M., Li P., et al. Safety and long-term immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012, 205:733-744.
3. Morel S., Didierlaurent A., Bourguinon P., Delhaye S., Baras B., Jacob V., et al. Adjuvant system ASO3 containing α-tocopherol modulates innate response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
4. A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomized, multicenter, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11:91-101.
5. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without ASO3(A) adjuvant: a preliminary report of an observer-blind, randomized trial. Vaccine 2010, 28:1740-1745.
6. Scheifele D.W., Marty K., LaJeunesse C., Fan S.Y., Bjornson G., Langley J.M., et al. Strategies for successful rapid trials of influenza vaccine. Clin Trials 2011, 8:699-704.
7. Rubinstein E., Predy G., Sauvé L., Hammond G.W., Aoki F., Sikora C., et al. The responses of aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. Can Med Assoc J 2011, 183(13):E1033-E1037. 10.1503/cmaj.110196.
8. Wood J.M., Newman R.W., Pless K. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev Biol 2003, 115:9-16.
9. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. Document EMEA/CHMP/VWP/263499/2006.
10. European Medicine Agency. CHMP recommendations for the pharmacologic vigilance plan as part of the risk management plan to be submitted with the marketing authorization application for a pandemic influenza vaccine. Report No. EMEA/359381/2009 rev. EMA; 2009.
11. A-adjuvanted influenza A (H1N1) vaccine for adults up to 85 years of age. Clin Infect Dis 2010, 51:668-677.
12. Gasparini R., Schioppa F., Lattanzi M., Barone M., Casula D., Pellegrini M., et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects. Int J Clin Pract 2009, 10.1111/j.1742-1241.2009.02309.x.
13. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicenter, randomized controlled trial. Lancet 2010, 375:49-55.
14. Wu J., Zhong X., Li C.K., Zhou J.F., Lu M., Huang K.Y., et al. Optimal vaccine strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. Vaccine 2011, 29:1009-1016.
15. ® reported in the French military forces-2009-2010. Vaccine 2011, 29:2576-2581.